Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that a poster examining the effects of TONMYA(R) (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain. The congress is scheduled for Oct. 26-30, 2026, in Bangkok, Thailand.
The presentation matters because TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025. As the first new treatment for fibromyalgia in more than 15 years, the data to be shared at the congress could further validate its clinical profile and support its adoption among healthcare providers. For investors, the presentation offers an opportunity for Tonix to showcase its flagship medicine on a global stage, potentially enhancing awareness and credibility in the medical community. Full details of the announcement are available in the company's press release at https://ibn.fm/jFHh3.
Tonix is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, its CNS commercial infrastructure supports marketed products for acute migraine, including Zembrace(R) SymTouch(R) and Tosymra(R). The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Its broader CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio within IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms and disclaimers, visit https://www.TinyGems.com/Disclaimer.
